Treatment of primary central nervous system lymphoma

被引:21
作者
Shah, GD [1 ]
DeAngelis, LM [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
关键词
D O I
10.1016/j.hoc.2005.05.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Primary central nervous system lymphoma (PCNSL) describes a malignant non-Hodgkin's lymphoma (NHL) whose sole site of involvement is the central nervous system (CNS). The diagnosis of PCNSL must be differentiated from systemic NHL with metastasis to the CNS, which usually occurs late in the course of systemic disease. PCNSL accounts for approximately 4% to 7% of primary brain tumors, and its incidence has been increasing since the mid-1970s. Compared with other more common malignant primary brain tumors, PCNSL tends to be more amenable to radiotherapeutic and chemotherapeutic intervention. In this article, the authors review the standard treatment for upfront and recurrent PCNSL.
引用
收藏
页码:611 / +
页数:18
相关论文
共 68 条
[1]
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: An intent-to-treat analysis [J].
Abrey, LE ;
Moskowitz, CH ;
Mason, WP ;
Crump, M ;
Stewart, D ;
Forsyth, P ;
Paleologos, N ;
Correa, DD ;
Anderson, ND ;
Caron, D ;
Zelenetz, A ;
Nimer, SD ;
DeAngelis, LM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4151-4156
[2]
Treatment for primary CNS lymphoma: The next step [J].
Abrey, LE ;
Yahalom, J ;
DeAngelis, LM .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3144-3150
[3]
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma [J].
Alvarnas, JC ;
Negrin, RS ;
Horning, SJ ;
Hu, WW ;
Long, GD ;
Schriber, JR ;
Stockerl-Goldstein, K ;
Tierney, K ;
Wong, R ;
Blume, KG ;
Chao, NJ .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000, 6 (3A) :352-358
[4]
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma [J].
Arellano-Rodrigo, E ;
López-Guillermo, A ;
Bessell, EM ;
Nomdedeu, B ;
Montserrat, E ;
Graus, F .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (04) :219-224
[5]
Intracranial sarcomatous tumors of leptomeningeal origin [J].
Bailey, P .
ARCHIVES OF SURGERY, 1929, 18 (04) :1359-1402
[6]
LEPTOMENINGEAL TUMOR IN PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA - RECOGNITION, SIGNIFICANCE, AND IMPLICATIONS [J].
BALMACEDA, C ;
GAYNOR, JJ ;
SUN, M ;
GLUCK, JT ;
DEANGELIS, LM .
ANNALS OF NEUROLOGY, 1995, 38 (02) :202-209
[7]
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07 [J].
Batchelor, T ;
Carson, K ;
O'Neill, A ;
Grossman, SA ;
Alavi, J ;
New, P ;
Hochberg, F ;
Priet, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) :1044-1049
[8]
BATCHELOR TT, 2004, 40 ASCO ANN M NEW OR
[9]
Braaten KM, 2003, CLIN CANCER RES, V9, P1063
[10]
CANELLOS GP, 1981, CANCER TREAT REP, V65, P125